Research programme: enzyme-based Coeliac disease therapeutic - AMYRA Biotech

Drug Profile

Research programme: enzyme-based Coeliac disease therapeutic - AMYRA Biotech

Alternative Names: Gluten-targeting enzymes - AMYRA

Latest Information Update: 23 Apr 2014

Price : $50

At a glance

  • Originator AMYRA Biotech AG
  • Class Enzymes
  • Mechanism of Action Enzyme replacements; Gluten inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Coeliac disease

Most Recent Events

  • 10 Apr 2014 Early research in Coeliac disease in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top